Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Changes in blood metabolomes as potential markers for severity and prognosis in doxorubicin-induced cardiotoxicity: a study in HER2-positive and HER2-negative breast cancer patients

Fig. 2

LVEF (A), E/e’ Ratio (B), LF/HF ratio (C), Plasma Troponin I (D), Plasma NT-proBNP (E), and Cellular Oxidative Stress in Peripheral Blood Mononuclear Cells (F) in HER2-Positive Breast Cancer Patients At Baseline Versus 2 Weeks After Completion of Doxorubicin Treatment. n = 37. Data are reported as mean ± standard error of the mean (SEM). *p < 0.05 when compared to baseline. LVEF = Left ventricular ejection fraction; E/e’ ratio = Early mitral inflow velocity-to-mitral annular early diastolic velocity ratio; LF/HF ratio = Low frequency-to-high frequency ratio; NT-proBNP = N-terminal pro B-type natriuretic peptide; DCF = Dichlorofluorescein

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us